This post is unavailable.
Join now Sign in
More Relevant Posts
-
Aziz BENREBBAH
Head of Manufacturing and Supply General Medicine Quality
- Report this post
Reflecting on My First 100 Days: Transforming Gen Med Quality Operations at SanofiDear NetworkAs I reflect on my first 100 days as Head of Quality Operations for General Medicine at Sanofi, I'm excited to share the journey and accomplishments so far. The past few months have been a whirlwind of activity, engagement, and impactful initiatives.🌍 Transformational Programs and Site Visits : I've had the privilege of participating in several transformational programs for Anagni and Frankfurt, and contributing to an initiative aimed at standardizing our quality organization. My commitment to understanding our operations firsthand led me to visit nine sites in 100 days: Aramon, Sisteron, Amilly, Ambares, Frankfurt (twice), Shenzhen, Hangzhou, and Beijing. In June, I'll continue this journey with visits to Frankfurt (again!), Riells, and Budapest, fulfilling my goal to visit half of my perimeter before summer.🏗️ Key Investments and Crisis Management : I've been involved in critical investment projects to enhance capacity and compliance of our products. Navigating the Euroapi Brindisi crisis has been a significant challenge, ensuring supply continuity and reinforcing our resilience.📈 Strategic Planning and Productivity : Working on the strategic planning for 2026-2030 has been ahighlight, with ambitious productivity plans targeting top decile performance. This strategic foresight is essential for our future success and competitiveness.👥 Welcoming New Leadership : A warm welcome to Stefan Bokstaller, my new functional boss. Together, we aim to drive our quality operations to new heights. Welcome, Stefan!💻 Digitalization Initiatives : I'm thrilled to kick off two major digitalization initiatives: the LIMS program in Frankfurt and the paperless initiative for the GenMed perimeter. These projects are pivotal in streamlining our processes and enhancing efficiency.🏥 Team Engagement and Networking : Meeting the teams during site visits and participating to the China Tour with Maité, our Chief Quality Officer and meeting the European Quality Leaders Network has been incredibly rewarding. Building strong relationships and fostering collaboration across our network is vital.🚀 Upcoming Drug Launches : We're gearing up for the registration and launches of two groundbreaking drugs in state-of-the-art plants in Sisteron, Aramon, Ambares, and Scoppitto: Tolebrutinib for Multiple Sclerosis and Rilzabrutinib for Asthma. These launches represent our commitment to bringing innovative treatments to patients worldwide.Thank you all for your continued support and encouragement. I’m honored to be part of such a dynamic and forward-thinking team.Together, we will achieve remarkable milestones and continue to transform our quality operations.Stay tuned for more updates as we drive forward with passion and purpose!Aziz#QualityLeadership #Innovation #Teamwork #Sanofi #100DaysOfImpact #DigitalTransformation #StrategicPlanning
105
10 Comments
Like CommentTo view or add a comment, sign in
-
Palash Gadge
Finance enthusiast | Equity Research Aspirant | Financial Modelling | Valuation
- Report this post
🚀 Mankind Pharma's Bold Move: Acquiring Bharat Serums and Vaccines for Rs 13,630 Crore 🚀Mankind Pharma is making its largest acquisition yet by acquiring Bharat Serums and Vaccines (BSV) at an enterprise value of Rs 13,630 crore. This strategic move aims to replicate their past M&A successes and solidify their position in the Indian healthcare market. 🌟🩺 Why BSV? BSV is a leading player in women's health, particularly in fertility and critical care. With a robust product portfolio and dominant market share, BSV aligns with Mankind Pharma's strategic focus on chronic therapeutic and consumer products. Additionally, BSV's sales growth of 17% per annum and an adjusted profit margin of 28% make it an excellent addition to Mankind Pharma's portfolio.💡 Strategic Synergies Leveraging its extensive sales network, Mankind Pharma is poised to scale BSV's business, further establishing itself as a market leader in the women’s health and fertility segment. This acquisition is set to enhance profitability, with the combined entity’s FY24 pro-forma EBITDA margin pegged at 25.2%.📊 Financial Considerations While the acquisition involves significant investment, Mankind Pharma has taken steps to mitigate financial risks. The company aims to reduce net debt/EBITDA to less than two times by FY26 and anticipates that the acquisition will add to net earnings from the second full year onwards.🔍 Track Record and Future Opportunities Mankind Pharma's successful acquisitions from Panacea Biotec and Dr Reddy’s Laboratories have set a strong precedent. BSV offers exciting opportunities, including a pipeline covering 12 of the top 15 infertility drugs and a specialized R&D tech platform. This acquisition will help fill portfolio gaps and strengthen Mankind Pharma's presence in women’s health therapies.As Mankind Pharma embarks on this new chapter, effective execution will be crucial. Stay tuned for updates as they integrate BSV and drive continued growth and innovation in the healthcare sector.#MankindPharma #Healthcare #Acquisition #PharmaIndustry #WomensHealth #Innovation #Growth #BusinessStrategy #MergersAndAcquisitions
10
2 Comments
Like CommentTo view or add a comment, sign in
-
Geoff McCleary
Global Digital Health Executive & Transformation Leader, Experienced Board Member, AI & Health Data Advisor to World Economic Forum, Host of the Digital Health Workbench podcast!
- Report this post
Lilly launches website, home delivery option for weight-loss drug reuters.comEli Lilly and Company launch #lillydirect . Not the first vertically integrated direct play from a manufacturer, but it is the first with a huge blockbuster behind it. The ways this will transform US healthcare, if successful, cannot be understated. Possibly this year’s most disruptive program…and we aren’t even done with the first week! Looking forward to everything else coming in 2024. #telemedicine #digitalhealth #weightloss Capgemini Life Sciences and Healthcare
19
1 Comment
Like CommentTo view or add a comment, sign in
-
Ryan Giefer
Operations Manager
- Report this post
How to connect with patients and love what you do. Let’s find a place for you.
6
Like CommentTo view or add a comment, sign in
-
Hernán Porcile
General Manager Mexico at Takeda
- Report this post
As we commemorate Takeda's 60th anniversary in Mexico, I am deeply thankful to Executive Forecast for the opportunity to participate in this interview. Takeda's evolution in Mexico over these 6 decades has been truly remarkable and has brought us to where we are today: an established biopharmaceutical leader specializing in innovative therapies for our patients. It was truly an honor to share Takeda Mexico's rich legacy and a part of our history:-60 Years in Mexico: In 2024, we will be celebrating a legacy of 6 decades in Mexico, enhancing the well-being of our patients and their families.-Mexico's Strategic Importance: Mexico is the first country with fully integrated operations for Takeda, including Commercial Operations, a Manufacturing Site, and an Innovation Capability Center.-Commitment to Integrity and Trust: We maintain a legacy of integrity, prioritize patient needs, foster a diverse and inclusive workforce, and focus on environmental sustainability.-Comprehensive Transformation: Over the last 5 years, we have transitioned into a biopharma and specialty care leader, driven by sustainable growth through innovation, ensuring access through collaboration, and building on internal talent and values.-Digitalization and AI: We use digital data and technology to enhance R&D and manufacturing, improve the patient experience, and support HCPs.#Takeda #Innovation #243Years
47
1 Comment
Like CommentTo view or add a comment, sign in
-
Jorge Cotes Calderón
Senior Global People Growth Manager at Boehringer Ingelheim
- Report this post
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains reuters.com4 weeks already, and I can say that I’m really happy I joined a company that is constantly challenging itself, by focusing not only on doing good but on doing it right.Challenging goals, and amazing and qualified people, is what drive Boehringer Ingelheim forward. And it’s that real, honest focus on people (employees, patients, customers) what I find so unique of BI.If I can summarise these 4 weeks in 4 words:✅ Collaboration✅ Openness✅ Transformation✅ BoldnessP.D.: And all of this pays off 👇🏽
82
4 Comments
Like CommentTo view or add a comment, sign in
-
Angelica Figueiredo White
Empowering Brands with the Direct Media Recording and Streaming from Products with Consumer Engagement | ZIPPYAR CEO | Revolutionizing Digital Marketing in Pharma, Retail, and CPG for Today's Generation.
- Report this post
“Reimagine medicine to improve and extend lives” ❤️The field of medicine is constantly evolving, and it is important for us to reimagine the possibilities beyond traditional chemical compounds and gene therapies. The holistic approach to healing is gaining momentum, and it is our moral obligation to ensure that the best treatments are accessible and affordable for everyone.I am eagerly looking forward to contributing to Novartis and other pharmaceutical companies by utilizing the innovative ZIPPYAR tech. Rather than using it solely for competitive advantage, I believe it can be a powerful tool to build strong relationships with healthcare professionals (HCPs). By focusing on helping patients access the best treatments in affordable ways, providing them with educational resources, promoting medication adherence, and actively seeking their feedback to improve treatment quality, we are not only supporting HCPs but also fostering meaningful connections with them.#digitalhealth #biotech #pharmaceutical #healthcare
6
1 Comment
Like CommentTo view or add a comment, sign in
-
Maria Galko
Saving lives & Transforming business
- Report this post
Bridging Innovations: The Synergy of Digital and Portfolio Transformation in HealthcareIn the span of my career, I've navigated the challenging yet rewarding paths of innovation, strategic portfolio management, and the unwavering commitment to enhancing patient care. My journey, which has taken me from the vibrant front lines of sales to the strategic echelons of business development, has been defined by a dedication to not just anticipate the future of healthcare, but to actively shape it.Currently, as the leader of the Specialty care at Swixx BioPharma in Almaty, Kazakhstan, I've had the distinct opportunity to focus on pivotal areas like oncology, immunology, and rare diseases. Our mission is clear: forge meaningful partnerships with pharmaceutical giants like Eli Lilly to deliver groundbreaking treatments to those in need. This role has not just been about leadership; it's been about vision, about seeing beyond the horizon to the next innovation that will redefine patient care.Reflecting on my tenure as the Omnichannel Lead for Sanofi, I'm reminded of the profound similarities between digital transformation and portfolio transformation. Both are about evolution, about moving from what is to what can be. At Sanofi, leading digital transformation efforts wasn't just about integrating new technologies; it was about fundamentally changing how we connected with healthcare professionals and patients. But what truly links digital and portfolio transformation is the mindset they require. Both demand a willingness to embrace change, to challenge the status quo, and to relentlessly pursue improvement. Whether it's leveraging VeevaCRM to enhance team efficiency, launching patient supprot program or driving partnerships that bring novel treatments to the market, the core objective remains the same: make a tangible difference, make this shift happen.As I continue on this journey, I am driven by the belief that the intersection of digital transformation and strategic portfolio management is where true healthcare innovation lies. It's a space where we can not only predict the future of patient care but also have a hand in creating it.I am proud of what we have accomplished so far and excited for what the future holds. #HealthcareInnovation #DigitalTransformation #PortfolioManagement #PatientCare #Leadership #StrategicPartnerships
17
Like CommentTo view or add a comment, sign in
-
Kevin Kruse
Founder @ LEADx | NY Times Bestselling Author
- Report this post
I’m excited to announce that we were just named a finalist for the Partnership Award.In partnership with Scott Tinkel and Craig Neverosky at Takeda and with Vaya Group, we designed and delivered a highly successful first-line leader program.The 12-month program helped elevate the skills of first-line sales leaders from good to great.We blended together in-person experiential workshops, virtual group coaching, and our digital system of pull-through to create a program that:-> was delivered largely in the flow of work-> reinforced learning in an ongoing way-> delivered measurable behavior change-> is highly replicable and affordable 🤓Already, the program has generated impressive results:->83% of leaders showed significant improvement in leadership performance (as evaluated by their supervisor).-> Qualitative feedback from supervisors indicates strong improvements in self-awareness, confidence, strategic thinking, communication skills, and more.-> The program’s NPS was 84 from participants & 100 from participants’ leaders.#leadershipdevelopmentP.S. More detail to come in a forthcoming Forbes article, as well as at LTEN Conference where Takeda will present a detailed breakdown of the workshop's design & delivery.
33
15 Comments
Like CommentTo view or add a comment, sign in
-
Executive Forecast
3,493 followers
- Report this post
Executive Forecast - Conversation: Hernán Porcile – General Manager, Takeda, Mexico executiveforecast.comWe are excited to share our interview with Hernán Porcile, General Manager of Takeda Mexico, just as the Japanese giant celebrates it's 243rd anniversary worlwide.Hernán highlights Takeda Mexico's impressive 60-year legacy of innovation in the country, marked by the opening of the ICC Innovation Center and significant investments in local manufacturing and R&D.He discusses Takeda's transformation from a primary company to a biopharma and specialty care leader through sustainable growth, access via collaboration, and a focus on internal talent and values. Mexico, as the first country with fully loaded operations, boasts around 550 employees and is achieving double-digit growth, ranking among the top 5 emerging markets with an extensive product range spanning GI, Oncology, Rare Diseases, Neuroscience, and Vaccines. Digitalization enhances their R&D, manufacturing, and patient care, reflecting their commitment to integrity and trust in healthcare.Hernán envisions a brighter future, recognizing Mexico's vast opportunities and high-potential talent, and positioning it as a global hub for innovation. Don't miss this insightful interview where Hernan delves deeper into Takeda Mexico's strategies and aspirations.#Innovation #Healthcare #Biopharma #TakedaMexico #Leadership #DigitalTransformation #PatientCare #Growth #Diversity #Talent #R&DJosé Manuel Caamaño IglesiasSameh Rafla Rodrigo Rodriguez Andrés HernándezHannah Kreher Mina Demirelhttps://lnkd.in/dGeuQ2cq
38
1 Comment
Like CommentTo view or add a comment, sign in
1,874 followers
- 20 Posts
View Profile
FollowExplore topics
- Sales
- Marketing
- IT Services
- Business Administration
- HR Management
- Engineering
- Soft Skills
- See All
